Mosunetuzumab
Mosunetuzumab (Lunsumio, Roche Registration GmbH) has 1 EU-approved indication in 1 tumour type.
| Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|
| Follicular lymphoma1 | |||
None | Monotherapy | 3L+ | After at least two prior systemic therapies |
Full text of section 4.1 (therapeutic indications)
Lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior systemic therapies.
Label history
11 changes to the Lunsumio label since 2023, none of them to the indications. Newest first, in the words of EMA's record of each procedure.
Changes